Drug Profile
Cannabidiol/tetrahydrocannabinol oral spray - Aphria/Medlab
Alternative Names: MDCNB-01; NanaBis; NanoCelle® d9-THC & CBD; Nanocelle™ CBDLatest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Aphria; Medlab
- Developer Medlab
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antidementias; Antiemetics; Antiepileptic drugs; Antihyperglycaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Appetite stimulants; Cannabinoids; Chromans; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Non-opioid analgesics; Obesity therapies; Phytotherapies; Skin disorder therapies
- Mechanism of Action 5-HT1 serotonin receptor modulators; Cannabinoid receptor agonists; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer pain
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for phase-I development in Cancer-pain in Australia (Buccal, Spray)
- 04 Nov 2021 Medlab Clinical has patent pending applications for NanoCelle® in multiple countries including Europe, Australia, Hong Kong, Singapore
- 04 Nov 2021 Medlab Clinical has patent protection for NanoCelle® in USA, New Zealand